Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a biopharmaceutical company focused on developing peptide-based drugs to address unmet medical needs. The company operates in the competitive pharmaceutical industry, where it faces rivals like Amgen and AbbVie. On March 18, 2026, Jefferies upgraded PTGX to a "Buy" rating, with the stock priced at $97.78 at the time.
The upgrade coincides with a major milestone for Protagonist Therapeutics. The U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an innovative interleukin-23 (IL-23) receptor antagonist. This approval is significant as ICOTYDE is the first oral peptide targeting IL-23R for treating moderate-to-severe plaque psoriasis in both adults and children aged 12 and older.
The FDA's approval of ICOTYDE is based on four phase 3 studies involving 2,500 patients, all of which met primary endpoints and showed a favorable safety profile. This achievement triggers a $50 million milestone payment for Protagonist Therapeutics. Additionally, the company is set to receive 6% to 10% royalties on sales and up to $580 million in future milestone payments.
Despite the positive news, PTGX's stock price is currently $97.09, reflecting a slight decrease of 0.14% or $0.14. The stock has fluctuated yesterday between $90.58 and $99.44. Over the past year, PTGX has seen a high of $99.45 and a low of $39.60, with a market capitalization of approximately $6.2 billion.
Protagonist Therapeutics plans to discuss this development further in a webcast and conference call scheduled for 8:30 am ET on March 18. The trading volume for PTGX on the NASDAQ is 1,948,990 shares, indicating active investor interest following the FDA approval announcement.
